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Rationale: The perception of fatigue in COPD has been associated with reduced health status.
We have shown that exacerbations are associated with reduced activity and health status.
However, the relationship between fatigue and exacerbation is unknown.
Objectives: To investigate the hypothesis that increased fatigue is related to physical inac-
tivity and COPD exacerbations.
Methods: Fatigue was studied in COPD and age-matched control subjects. The relationship
between fatigue and stable patient characteristics in COPD, and the effect of exacerbation
on fatigue were evaluated.
Measurements: 107 COPD patients mean age 69 years (range 43e86), FEV1 53% (SD 21), and 30
aged-matched control subjects; Functional Assessment of Chronic Illness Therapy-Fatigue
Scale, Centre for Epidemiological Studies Depression Scale.
Main results: Fatigue in COPD patients was significantly increased compared to control
subjects (mean 35.3 units (SD 11.0) versus 43.2 (10.5), pZ 0.001). Increase in fatigue in COPD
was related to reduced time spent outdoors (rZ0.43, p< 0.001), increase in depression
(rZ0.59, p< 0.001) and annual exacerbation frequency (rZ0.27, pZ 0.005).
Fatigue increased at exacerbation in 31/32 patients. Overall, fatigue increased by 8.3 units
(5.9), p< 0.001. Change in fatigue at exacerbation was related to increase in depression
(rZ0.46, pZ 0.008). Fatigue recovered at 6 weeks following exacerbation.
Conclusions: The perception of fatigue increased in patients with COPD compared to age-
matched control subjects, and associated with morbidity when patients were stable and at
exacerbation.
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Determinants of fatigue in COPD 217Introduction patients with completed diary cards. All COPD patients andChronic obstructive pulmonary disease (COPD) is charac-
terised by progressive airflow obstruction which is mainly
irreversible.1 It is associated with significant comorbid-
ities,2 and extrapulmonary manifestations. Fatigue, the
perception of mental or physical exhaustion due to exer-
tion, may be a common symptom in COPD,3,4 and it has
been associated with reduced health status, dyspnoea 5,6
and depression.6
COPD exacerbations are episodes of sustained deterio-
ration in respiratory symptoms associated with increased
systemic inflammation,7 muscle weakness,8 reduced lung
function,9 daily activity10,11 and health status.12 Exacer-
bations are responsible for 10% of emergency medical
admissions in the U.K,13 and associated with a significant
economic health-burden.14 Despite this, it is not known
whether fatigue increases at exacerbation and thus could
contribute to the morbidity of exacerbations including
depressive symptoms, or whether patients with more
frequent exacerbations have increased fatigue.
There is evidence to suggest that reduced physical
activity in COPD15 may lead to myopathy and weakness,16
associated with increased healthcare utilization11,17 and
poor prognosis.18 In contrast, exercise training as part of
pulmonary rehabilitation has been shown to improve the
perception of fatigue,19 functional exercise capacity19e21
and health status.19,20 However, the relationship between
the perception of fatigue and daily outdoor physical
activity10 has not been previously described.
This study investigated for the first time the relationship
between fatigue and exacerbations, fatigue and depression
at exacerbation, and the perception of fatigue and time
spent outdoors, an indicator of physical activity. Some of
the results of this study have been previously reported in
the form of abstracts.22e24
Methods
Recruitment of COPD patients and control subjects
107 patients with COPD and 30 control subjects were
recruited between April 2006 and November 2007 from the
London COPD cohort. This is a rolling cohort of COPD
patients and control subjects recruited from the commu-
nity and respiratory clinics to prospectively investigate the
mechanisms of COPD exacerbation.7,9,10,12 COPD was
defined as a post-bronchodilator forced expiratory volume
in 1 s to forced vital capacity ratio (FEV1/FVC) of less than
70%, and features consistent with the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines25 for
the diagnosis of COPD.
Control subjects had no previous history of COPD, with an
FEV1/FVC of more than 70%. All COPD patients and control
subjects with a history of malignant disease, immunodefi-
ciency, significant inflammatory or other respiratory disease
were excluded.
At recruitment COPD patients were in a stable condition,
at least four weeks from their last exacerbation. The
average daily time outdoors, over a period of 6 months
before and after assessment, was calculated for 86 COPDcontrol subjects were assessed with the MRC Dyspnoea
scale26 and a 10 cm Visual Analogue Scale at rest, (VAS,27).
Smoking status, smoking pack years and history of co-
morbidity was noted. Patient questionnaires (detailed
below) were also completed for assessment of fatigue using
the validated Functional Assessment of Chronic Illness
Therapy-Fatigue Scale (FACIT-Fatigue,28e30), depression
(with Centre for Epidemiologic Studies Depression Scale,
CES-D,31e33), and quality of life (with St. George’s Respi-
ratory Questionnaire, SGRQ,34). Height and weight were
measured, in addition to baseline pulse oximetry (digital
Minolta Pulsox TS-7, Japan), and lung function using
a volumetric storage spirometer (Vitalograph 2160, Buck-
ingham, England). For patients with obstructive spirometry,
an assessment of reversibility to B2-agonist was made, after
inhalation of 400 mcg salbutamol from a metered-dose
inhaler via spacer.
All COPD patients were phenotyped by providing a 7 ml
sample of blood for measurement of haemoglobin (Hb,
Advia 2120 Haematology System, Siemens Medical Solutions
Diagnostics, New York, U.S.) and serum C-reactive protein
(CRP, using an Olympus luminometric analyzer (Olympus
Life and Material Science Europa GmbH, Hamburg,
Germany) within 2 h. The limit of detection for serum CRP
was 0.3 mgl1.
This study was approved by the Royal Free Hospital
Research Ethics Committee and all patients gave written
informed consent. Some of the depression scores in COPD
patients have been reported in a study of COPD and
depression,35 but the data of fatigue which is the main
focus of this paper has not been previously published.Self-complete questionnaires
The FACIT-Fatigue is a simple 13 point questionnaire which
provides a validated measure of the level of fatigue in
chronic disease28,29 and relates to performance status. The
response to each question is measured on a scale of 0e4,
and scored such that the minimum overall score of
0 reflects the highest level of fatigue measurable and the
maximal score of 52 reflects the lowest possible level of
fatigue.30 This paper refers to fatigue as a symptom from
here onwards, but it should be noted that with this ques-
tionnaire, a higher FACIT-Fatigue score indicates less
fatigue.
The CES-D is a 20 point questionnaire which assesses the
prevalence of depression and magnitude of change and
associated symptoms in COPD31 and the general pop-
ulation.32 This depression questionnaire excludes somatic
symptoms such as fatigue. Only completed questionnaires
were used to calculate a CES-D score which has a maximum
attainable score of 60. A score of 16 or higher is consistent
with clinical depression, according to validation studies
comparing it to the fourth edition of Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria for
clinical depression.33
The SGRQ34 measures health impairment in patients with
respiratory disease and has three component scores which
provide a measure of the effects of disease on the domains
of symptoms, activity and impact.
218 R. Baghai-Ravary et al.COPD exacerbation and follow-up
COPD patients in the London COPD cohort were trained
to complete daily diary cards of time spent outdoors and
any increase in respiratory symptoms. All patients with
COPD were routinely seen three monthly in clinic, where
diary cards were reviewed and spirometry was recorded.
Patients were asked to contact our study team when
experiencing increase in daily symptoms and usually
seen within 48 h for assessment of symptoms and
confirmation of exacerbation according to the definition
described later. Some patients did not report their
exacerbations at onset and therefore fatigue was
measured at a median of 4.3 days. Data collected after
14 days after the onset of an exacerbation was
excluded. All patients were assessed prior to initiation
of therapy for exacerbation with follow-up arrangement
for 6 weeks from an exacerbation onset.
Definition of exacerbation
Exacerbations were identified using patient diary cards, by
our previously validated criteria7,9,10,12 of two consecutive
days of two symptoms or more with at least one major
symptom, or if in the opinion of the attending clinician the
patient was exacerbating. Major symptoms were an
increase in dyspnoea, sputum volume or purulence and
minor symptoms were increase in cough, wheeze, sore
throat or symptoms of a cold (increase in nasal congestion
or discharge).Table 1 Stable characteristics of 107 stable COPD patients and
107 stable
COPD patients
Stable data for
subgroup of 32
patients seen a
an exacerbation
Mean SD Mean SD
Age (years) 69.4 8.2 65.9 9.
FEV1 (litres) 1.3 0.6 1.3 0.
FEV1(% predicted) 53.1 21.1 51.5 20
FVC (litres) 2.8 1.0 2.7 0.
BMI (kgm2) 25.9 5.4 26.4 4.
FACIT-Fatigue Scale 35.3 11.0 33.7 9.
CES-D scale 14.0 11.2 13.0 9.
VAS (0e10 cm) 4.4 2.3 4.9 2.
TOTAL SGRQ score 49.2 18.0 54.0 16
Activity domain 65.2 23.0 67.2 19
Impact domain 36.1 19.3 41.3 18
Symptom domain 62.3 20.0 70.7 17
Haemoglobin (g/dl) 14.0 1.8 14.0 1.
Median IQR Median IQ
Smoking pack years 49 32e71 48 32
Annual exacerbation
incidence/yr
2 0e3 3 2e
MRC dyspnoea 3 2e4 3 2e
SaO2 (% on air) 95 94e96 95 94
CRP (mg/l) 4 2e7 4 2eExacerbation frequency
The annual exacerbation incidence was determined from
diary cards in the year prior to recruitment for 96 patients.12
In 11 patients who withdrew within one year, the self-
reported exacerbation history was used. The median annual
exacerbation incidence was 2 per year (interquartile range,
IQR 0e3). 55 patients with 2 or more exacerbations per year
were defined as frequent exacerbators and the remaining 52
patients as infrequent exacerbators.
Statistical analysis
The data was analysed using SPSS version 11 (SPSS Inc,
Chicago, U.S.). Parameters were tested for normality using
the KolmogroveSmirnov test. Normally distributed data
were expressed as mean and standard deviation (SD), and
skewed data as median and interquartile range (IQR).
Correlations were assessed by Pearson or Spearman’s rank
correlation as appropriate. Differences in fatigue between
patients grouped according to categorical parameters such
as MRC Dyspnoea scale or GOLD staging were assessed by
a one-way ANOVA. An unpaired t-test was used to test the
effect of co-morbidity on fatigue. Mutiple regression anal-
ysis was used to ascertain the relative contribution of
factors related to fatigue. A single fatigue measurement
when the patient was stable and the first reported exac-
erbation were selected to avoid bias and to simplify anal-
ysis. Paired t-test analyses were used to evaluate fatigue in
the stable state compared to exacerbation, and at 6 weeks32 patients subsequently seen at exacerbation.
t
Stable data for
subgroup of 75
patients not seen
at an exacerbation
Comparison of
stable characteristics
between 2 subgroups
Mean SD p value
2 70.9 7.3 0.004
6 1.3 0.6 0.71
.7 54.0 21.6 0.54
9 2.8 1.0 0.59
5 25.7 5.7 0.58
6 36.0 11.6 0.34
9 14.5 11.7 0.55
0 4.2 2.4 0.13
.4 47.2 18.3 0.07
.8 64.3 24.3 0.55
.6 33.9 19.4 0.07
.7 58.7 20.0 0.004
5 14.1 2.0 0.95
R Median IQR
e56 49 32e82 0.29
4 1 0e2 <0.001
4 3 2e4 0.83
e96 95 94e97 0.47
6 5 2e8 0.59
Table 2 Characteristics of 107 stable COPD patients compared with 30 control subjects.
107 stable COPD patients 30 Control patients Comparison of stable
characteristics
Mean SD Mean SD p value
Age (years) 69.4 8.2 68.6 6.1 0.61
FEV1 (litres) 1.3 0.6 2.3 0.8 < 0.001
FEV1 (% of predicted) 53.1 21.1 94.1 16.9 < 0.001
FVC (litres) 2.8 1.0 3.0 1.0 0.38
BMI (kgm2) 25.9 5.4 26.3 6.0 0.74
FACIT-Fatigue Scale 35.3 11.0 43.2 10.5 0.001
VAS (0e10 cm) 4.4 2.3 0.6 1.2 < 0.001
TOTAL SGRQ score 49.2 18.0 13.2 17.7 <0.001
Activity domain 65.2 23.0 19.3 23.4 <0.001
Impact domain 36.1 19.3 7.7 15.3 <0.001
Symptom domain 62.3 20.0 19.9 24.9 <0.001
Median IQR Median IQR
CES-D scale 11.0 5.0e20.0 7.5 3.0e11.0 0.026
Smoking pack years 49 32e71 15 0e34 <0.001
MRC dyspnoea 3 2e4 1 1e1 <0.001
SaO2 (% on air) 95 94e96 96 96e97 0.001
F
A
C
I
T
-
F
a
t
i
g
u
e
 
S
c
a
l
e
52
39
26
13
0
MRC Dyspnoea Scale
54321
n = 4
Annova p < 0.001
Less
Fatigue
More
Fatigue
35  33  22 43
Figure 1 Box plot showing fatigue (mean and standard error,
SEM) in patients with COPD at different levels of dyspnoea.
Determinants of fatigue in COPD 219follow-up. A p-value< 0.05 was taken as statistically
significant for all tests.
Results
Patient characteristics
Table 1 shows the stable characteristics for 107 COPD
patients (64 male), and a comparison of stable character-
istics of a subset of 32 COPD patients seen at exacerbation
with the remaining 75 COPD patients seen only when
stable. Compared with patients who were not seen at
exacerbation, patients seen at exacerbation were signifi-
cantly younger, had a higher annual exacerbation incidence
and poorer health status.
The stable characteristics of 107 COPD patients are
compared with 30 control subjects in Table 2. These two
groups were age-matched, but the COPD patients had
a higher smoking pack year history. Patients with COPD had
increased fatigue compared to control patients (thus
a lower mean fatigue score of 35.3 units (SD 11.0) versus
43.2 (10.5), pZ 0.001); median values were 37 (IQR 28e44)
compared to 45 (39e50) respectively.
Fatigue in stable COPD
There was no relationship between fatigue and severity of
COPD. In 107 stable COPD patients, fatigue was unrelated
to FEV1 (rZ 0.1; pZ 0.3), FEV1 % predicted (rZ 0.1;
pZ 0.2), and FVC (rZ 0.2; pZ 0.1). There was also no
association between fatigue and GOLD staging (ANOVA
pZ 0.07) or oxygen saturation (rZ0.1; pZ 0.5).
However, increase in fatigue in COPD was significantly
related to increased perception of dyspnoea when assessed
by the MRC Dyspnoea scale (ANOVA p< 0.001, Fig. 1) or VAS
(rZ0.34; p< 0.001). Fatigue was also related to reducedquality of life (higher total SGRQ, rZ0.61; p< 0.001,
Fig. 2), and to the activity, impact and symptom domains of
the SGRQ (rZ0.44; rZ0.65; rZ0.36 respectively,
and p< 0.001 for all three domains).
In stable patients, higher fatigue was related to higher
depressive symptoms score (rZ0.59; p< 0.001, Fig. 3). A
depression score consistent with clinical depression (CES-D
16) was associated with greater fatigue (mean 27.6 units
(SD 10.7) versus 40.0 (8.4); p< 0.001).
The mean daily time spent outdoors was 3.0 h (2.3).
Increased fatigue was related to reduced time spent
outdoors (rZ0.43, p< 0.001). On multiple regression
analysis of factors associated with time spent outdoors,
increased fatigue remained the only factor significantly
associated with reduced time spent outdoors (Table 3).
COPD patients with a history of ischaemic heart disease
had greater fatigue 30.0 (13.5) than remaining patients at
36.2 (10.4), pZ 0.04. However, on multiple regression
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Figure 2 Scatter plot showing correlation between fatigue
and health status in COPD.
Table 3 Multiple regression analysis of factors associated
with reduced time spent outdoors in COPD.
Regression
coefficient
Standard
error
p value
FACIT-Fatigue scale 0.36 0.03 0.007
CES-D score 0.06 0.03 0.89
FEV1 % of predicted 0.11 0.01 0.32
Total SGRQ 0.13 0.02 0.43
MRC dyspnoea scale 0.28 0.29 0.054
220 R. Baghai-Ravary et al.analysis (Table 4), the association between fatigue and IHD
was not statistically significant after allowance for other
related factors. There was no association between fatigue
and sex, current smoking status, smoking pack years, other
comorbidities, levels of Hb or CRP, p> 0.05.
Fatigue and COPD exacerbation
Higher annual exacerbation frequency in stable patients
was related to increased levels of fatigue (rZ0.27;
pZ 0.005). Fig. 4 shows that frequent exacerbators were
significantly more fatigued than infrequent exacerbators
(pZ 0.002).
Increase in fatigue was a common feature of exacerba-
tion (31/32 patients) at 4.3 (2.9) days from the onset of
exacerbation symptoms. Compared to stable values, at
exacerbation there was an overall increase in fatigue of 8.3
units (5.9) p< 0.001, Fig. 5; median values were 37 (28e44)
in stable patients and 25 (18e32) at exacerbation. Fatigue
at exacerbation was related to stable levels, rZ 0.81,
p< 0.001.
At exacerbation there was a significant increase in
depression of 6.9 units (10.1), pZ 0.003. Fatigue and
depression at exacerbation were related (rZ0.66;F
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Figure 3 Scatter plot showing correlation between levels of
fatigue and depression scales, and fatigue scores in patients
who had a CES-D consistent with depression compared to others.p< 0.001) and the increase in fatigue at exacerbation was
related to change in depression (rZ0.46; pZ 0.008).
Exacerbation was associated with a reduction in FEV1 of
0.13 l (0.28), pZ 0.006. Increase in fatigue at exacerbation
compared to the stable state was related to the reduction
in FEV1 (rZ 0.36; pZ 0.04) at exacerbation.
In 17 patients, who attended clinic 6 weeks post exac-
erbation onset, without an intervening exacerbation,
fatigue was not significantly different from stable levels
(pZ 0.53, Fig. 5).
Discussion
In this study, we have demonstrated that the perception of
fatigue in stable COPD was increased compared to age-
matched control subjects. Increased fatigue in COPD was
related to impairment of other important outcomemeasures
such as dyspnoea, exacerbation frequency, health status
and time spent outdoors, but not disease severity as
assessed by FEV1 or GOLD staging. At exacerbation there was
a significant increase in the level of fatigue, related to
a reduction in FEV1. Patient fatigue recovered 6 weeks post
exacerbation.
The perception of fatigue, whether due to mental or
physical exhaustion, is a recognised symptom in the general
population and a feature of chronic diseases.28,29,36e38 The
median fatigue of 37 units in our cohort of stable COPD
patients was higher than in control subjects at 45, and
higher than values reported by Cella30 for the general
population at 47 and non-anaemic patients with cancer at
42. At exacerbation the level of fatigue in COPD patients, at
a median of 25 units, was comparable with that found in
anaemic patients with cancer at 23.30 These findingsTable 4 Multiple regression analysis of factors associated
with fatigue in COPD.
Regression
coefficient
Standard
error
p value
Time spent outdoors 1.23 0.42 0.004
Visual analogue
score of dyspnoea
1.18 0.42 0.007
Annual exacerbation
frequency
0.99 0.46 0.033
Depression (CES-D score) 0.37 0.09 <0.001
IHD 4.40 2.42 0.073
Exacerbation Frequency
FrequentInfrequent
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Figure 4 Relationship between stable fatigue levels (mean
and SEM) and exacerbation frequency.
Determinants of fatigue in COPD 221suggest that fatigue is increased and clinically relevant
both in stable COPD and at exacerbation.
In stable patients, we did not find a relationship
between the perception of fatigue and FEV1 or GOLD
staging. This lack of correlation between fatigue and
severity of disease in stable patients may be related to an
adaptation to chronic impairment. The increase in fatigue
at acute exacerbation was related to change in FEV1.
Dyspnoea at COPD exacerbation is predominantly related to
a reduction in vital capacity of lungs due to dynamic
hyperinflation,39,40 which is better reflected by a reduced
inspiratory capacity (IC) than by change in FEV1. Since the
perceptions of dyspnoea and fatigue are related, we
speculate that a mechanism of increase in fatigue at
exacerbation may be an increase in work of breathing
through a similar pathway, and that increase in fatigue at
exacerbation may also therefore be more closely related to
change in IC than FEV1.
Fatigue in COPD forms an important component of
health status,5 which is reduced at exacerbation.12,41 This
study was not designed to detect a clinically significant
change in fatigue, but we estimated that an increase in
fatigue of 1.50 units would be associated with a four point
increase in the total SGRQ scale, accepted as the minimum
clinically significant change in health status.42 Our finding6 week follow-upExacerbationStable
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Figure 5 Box plot showing fatigue (Mean and SEM) at exac-
erbation and on follow-up in 17 patients with COPD.of an 8 unit increase in fatigue at exacerbation may
therefore be related to a very significant reduction in
health status during exacerbation. Fatigue may contribute
to the morbidity and healthcare costs21 associated with
exacerbations.
The level of fatigue in stable patients correlated with
fatigue at exacerbation. Therefore, if fatigue is an impor-
tant determinant of activity and increased need for social
support, monitoring fatigue may allow early identification
of COPD patients who are most likely to benefit from
community support, facilitated discharge from hospital, or
therapy directed at fatigue (discussed later).
We and others6 have shown a relationship between
fatigue and depression in COPD, which persists at exacer-
bation. It should be noted that our assessment of depres-
sion was independent of somatic symptoms such as fatigue
and that the FACIT-Fatigue scale provides a measure of
performance status due to fatigue symptoms. Whether
fatigue is a cause or symptom of depression, effective
strategies need to be developed to address fatigue and
associated physical inactivity in addition to any underlying
depression.
Fatigue recovered to stable levels within 6 weeks of
COPD exacerbation, in patients without an intervening
exacerbation. The number of non-recovered exacerbations
was two, and a further 8 patients had recurrent exacer-
bation within 6 weeks. We were therefore unable to form
any conclusion on the relevance of fatigue in persistent
exacerbation. In stable COPD, increase in fatigue was
related to increase in exacerbation frequency. The rela-
tionship between fatigue and exacerbation frequency may
be due to increase in physical inactivity at and around
exacerbation,10,11 propagating a downward cycle of muscle
de-conditioning, further fatigue, and weakness which has
been associated with recurrent exacerbation,11 healthcare
utilization17 and increased mortality.18 These findings are
supported by our finding that an increase in the perception
of fatigue was related to a reduction in mean time spent
outdoors, an indicator of physical activity, and a reduction
in activity related health status. The relevance of the
perception of fatigue in COPD is underlined by our finding
on multiple regression analysis that fatigue remained the
only factor significantly related to time spent outdoors
(Table 3). However, we acknowledge that reported time
spent outdoors does not measure different levels of phys-
ical activity.
There was no evidence of a relationship between fatigue
in stable COPD and CRP levels, consistent with the
suggestion that systemic inflammation does not play a part
in the pathophysiology of fatigue. Fatigue in COPD was
associated with a history of ischaemic heart disease (IHD),
but this relationship was not significant in a multiple
regression analysis (Table 4). Fatigue is a recognised
feature of congestive cardiac failure (CHF) but not IHD, and
this study was not designed to evaluate the role of fatigue
in patients with COPD and coexisting CHF.
Exercise training as part of pulmonary rehabilitation
leads to significant improvement in functional exercise
capacity and health status in stable COPD.19e21 These
beneficial effects have also been demonstrated following
COPD exacerbation.43 There is evidence to suggest that
exercise rehabilitation may also reduce fatigue (indicated
222 R. Baghai-Ravary et al.by an increase in the fatigue domain of the CRQ,19,43),
emergency hospital admission43 and days spent in hospital19
following subsequent exacerbation. Early recognition of
fatigue in patients with COPD, may therefore allow iden-
tification of patients who are likely to benefit from imple-
mentation of early exercise rehabilitation, prior to
hospitalisation and progression of morbidity associated with
inactivity. Our study suggests that assessment of fatigue in
COPD patient may serve as an important indicator of
physical inactivity (Table 3) and coexisting depression
(Fig. 3) which should be addressed. Further research is
needed to determine the optimal mode and frequency of
exercise training, and to investigate other strategies for
reducing fatigue in COPD.
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